August 13, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Thursday, August 13, 2026

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, M/s Zota Health Care Limited (the "Company"), would like to inform you that the Board of Directors of the Company in its Meeting held on Thursday, August 13, 2026 at 05:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have *inter alia*, discussed and approved the following businesses:

1. Considered and approved Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026 along with the Limited Audit Report thereon. Financial Results and Limited Audit Report are enclosed herewith ***(Annexure-1)***.

   We would like to inform you that M/s. Pradeep K. Singhi & Associates, Chartered Accountants, Statutory Auditors of the Company, have issued the Limited Audit Report with Unmodified review conclusion. Further, Standalone and Consolidated Unaudited Financial Results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com.

The Board meeting concluded at 6:05 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,
For Zota Health Care Limited

Ashvin Bhagavanbhai Variya
Digitally signed by Ashvin Bhagavanbhai Variya
Date: 2026.08.13 18:34:18 +05'30'

Ashvin Variya
(Group Company Secretary & Compliance Officer)

Place: Surat
Encl.: a/a

Registered Office:
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter ended June 30, 2026** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (the "Regulations").

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pradeep K Singhi & Associates

Chartered Accountants

FRN : 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI Date: 2026.08.13 18:10:04 +05'30'

Date: 13-08-2026

Place: Surat

Pradeep Kumar Singhi

(Partner)

M. No. 200/024612

UDIN: 26024612XVXFSJ1864

zota® healthcare ltd.

ZOTA HEALTH CARE LIMITED

Unaudited Standalone Financial Results for the quarter ended 30th June, 2026

(Amount ₹ in Lakhs)

	Particulars	Quarter Ended			Year Ended
		30-06-26 (Unaudited)	31-03-26 (Audited)	30-06-25 (Unaudited)	31-03-26 (Audited)
I.	Revenue from Operations	12702.91	12070.05	7800.70	40700.72
II.	Other Income	394.26	410.33	223.39	1340.18
III.	**Total Income**	**13097.17**	**12480.38**	**8024.09**	**42040.91**
IV.	**Expenses:**				
	Cost of Materials Consumed	236.97	360.44	490.52	1746.43
	Purchases of Stock-in-Trade	7704.85	8930.20	3442.21	23674.65
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(830.13)	(2385.93)	536.90	(2550.99)
	Employee Benefit Expenses	1238.95	1548.10	997.58	4889.32
	Finance Costs	29.86	8.34	3.68	25.26
	Depreciation / Amortisation and Depletion Expense	126.88	125.33	79.68	395.43
	Other Expenses	4329.54	3082.76	1618.96	9785.45
	Total Expenses	**12836.92**	**11669.23**	**7169.54**	**37965.54**
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	260.25	811.15	854.56	4075.36
VI.	Exceptional Items		(98.96)		(98.96)
VII.	Profit/(loss) before tax	260.25	712.19	854.56	3976.40
VIII.	Tax Expense:				
	(1) Current tax	75.99	264.00	223.68	1095.36
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	0.00	-	(10.95)
	(2) Deferred Tax	5.46	160.69	(40.44)	(101.34)
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	189.72	608.87	590.44	2790.66
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII.	**Profit/ (Loss) for the period**	**189.72**	**608.87**	**590.44**	**2790.66**
XIV.	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified to Statement of profit and loss	(34.60)	31.02	(16.09)	50.81
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	8.71	(7.81)	4.05	(12.79)
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-
	Other comprehensive income for the period, net of tax	(25.90)	23.21	(12.04)	38.02
	Total comprehensive income for the period (XIII + XIV)	**163.82**	**632.09**	**578.40**	**2828.68**
	Paid-up Equity Share Capital	3463.26	3463.26	2976.66	3463.26
	Other Equity				85356.94
	Earnings per equity share of face value of ₹ 10 each				
	(1) Basic (in ₹)	0.55	1.77	2.03	8.48
	(2) Diluted (in ₹)	0.55	1.77	1.88	8.48

* denotes figures less than a lakh

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota (Din : 01097722)

(Managing Director) Moxesh K. Zota (Din : 07625219)

ZOTA HEALTHCARE LTD.

Group CS Ashvin Variya

Chief Financial Officer Viral Mandviwala

Date: 13-08-2026

Place : Surat

For Pradeep K. Singhi & Associates

Chartered Accountants

Firm No. 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI Date: 2026.08.13 18:10:28 +05'30'

Pradeep Kumar Singhi

(Partner)

M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

CIN : L24231GJ2000PLC038352

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") **and its subsidiaries** (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter ended June 30, 2026** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as amended from time to time (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

i. Zota Health Care Limited (Parent)
ii. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
iii. Davaindia Health Mart Limited (Wholly Owned Subsidiary)

iv. Zota Nex Tech Limited (Wholly Owned Subsidiary)
v. Everyday Herbal Beauty Care Limited (Subsidiary)
vi. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)
vii. Curexis Ventures Private Limited (Wholly Owned Subsidiary)
viii. Globotask It Consultancy Services Private Limited (Subsidiary)
ix. KMHP Ventures Limited(Wholly Owned Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited total revenues of Rs. 11548.44 Lakhs, total net profit/(loss) after tax of Rs. (3904.52) Lakhs and total comprehensive income of Rs. (3975.78) Lakhs, for the quarter ended June 30, 2026 , as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Pradeep K Singhi & Associates

Chartered Accountants

FRN : 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI
Date: 2026.08.13 18:10:49 +05'30'

Date: 13-08-2026
Place: Surat

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612
UDIN: 26024612UVLHWE4626

zota® healthcare ltd.

ZOTA HEALTH CARE LIMITED

Unaudited Consolidated Financial Results for the quarter ended 30th June, 2026

(Amount ₹ in Lakhs)

	Particulars	Quarter Ended			Year Ended
		30-06-26	31-03-26	30-06-25	31-03-26
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I.	Revenue from Operations	17360.23	16317.53	10358.26	53865.75
II.	Other Income	204.34	320.80	87.61	743.75
III.	**Total Income**	**17564.57**	**16638.33**	**10445.87**	**54609.50**
IV.	**Expenses:**				
	Cost of Materials Consumed	236.97	360.44	490.52	1746.43
	Purchases of Stock-in-Trade	8395.81	10797.91	4185.61	28534.72
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(2028.55)	(5196.64)	(162.85)	(8884.30)
	Employee Benefit Expenses	6112.50	5443.49	3317.31	17832.98
	Finance Costs	635.24	532.25	323.90	1736.11
	Depreciation / Amortisation and Depletion Expense	2774.84	2701.13	1467.84	8245.31
	Other Expenses	5803.24	4041.96	2132.02	12781.94
	Total Expenses	**21930.04**	**18680.53**	**11754.35**	**61993.19**
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	(4365.47)	(2042.20)	(1308.48)	(7383.69)
VI	Exceptional Items	-	(599.98)	-	(599.98)
VII.	Profit/(loss) before tax	(4365.47)	(2642.18)	(1308.48)	(7983.67)
VIII.	Tax Expense:				
	(1) Current tax	75.99	264.00	244.25	1095.36
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	0.00	-	(10.95)
	(2) Deferred Tax	46.99	1459.99	174.94	1660.34
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(4394.47)	(1446.19)	(1377.79)	(7407.74)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII.	**Profit/ (Loss) for the period**	**(4394.47)**	**(1446.19)**	**(1377.79)**	**(7407.74)**
XIV.	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified to Statement of profit and loss	(129.66)	103.22	(14.04)	204.36
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	32.48	(25.86)	3.53	(51.19)
	B (i) Items that will be reclassified to Statement of profit and loss	0.02	(0.00)	0.01	*
	(ii) Income Tax relating to items that will be reclassified to profit and loss	*	0.00	*	*
	Other comprehensive income for the period, net of tax	**(97.16)**	77.36	**(10.51)**	**153.17**
	Total comprehensive income for the period (XIII + XIV)	**(4491.63)**	**(1368.83)**	**(1388.29)**	**(7254.56)**
	Profit attributable to:				
	Owners of the parent	(4355.51)	(1416.82)	(1431.58)	(7393.61)
	Non-controlling interest	(38.96)	(29.37)	53.79	(14.13)
	Other comprehensive income attributable to:				
	Owners of the parent	(96.67)	77.36	(12.08)	152.42
	Non-controlling interest	(0.49)	0.00	1.57	-
	Total Comprehensive Income attributable to:				
	Owners of the parent	(4452.19)	(1339.47)	(1443.66)	(7241.19)
	Non-controlling interest	(39.45)	(29.37)	55.37	(14.13)
	Paid-up Equity Share Capital	3463.26	3463.26	2976.66	3463.26
	Other Equity				64481.81
	Earnings per equity share of face value of ₹ 10 each				
	(1) Basic (in ₹)	-12.58	-4.13	(4.92)	(22.46)
	(2) Diluted (in ₹)	-12.58	-4.13	(4.56)	(22.46)

* denotes figures less than a lakh

For and on behalf of the Board

(Whole-time Director) Himanshu M. Zota (DIN : 01097722)

(Managing Director) Moxesh K. Zota (DIN : 07625219)

Group CS Ashvin Variya

Chief Financial Officer Viral Mandviwala

Date: 13-08-2026

Place : Surat

ZOTA HEALTHCARE LTD. *

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI Digitally signed by PRADEEP KUMAR SINGHI Date: 2026.08.13 18:11:08 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

zota®
healthcare ltd.

Notes:

1. The above financial results for the quarter ended June 30, 2026 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on August 13, 2026.

2. The Financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.

3. The figures for quarter ended March 31, 2026 are balancing figures between the audited figures of the financial year ended March 31, 2026 and the published figures of the year-to-date (nine months) ended December 31, 2025, which were subjected to limited review report.

4. The Statutory Auditors have carried out Limited Review with Unmodified review conclusion of the financial results for the quarter ended June 30, 2026.

5. The Company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.

6. The Consolidated results include the result of following Companies:
   A) Wholly Owned Subsidiaries:
      i) Zota Healthcare Lanka (Pvt) Ltd
      ii) Davaindia Health Mart Limited
      iii) Zota Nex Tech Limited
      iv) Curexis Ventures Private Limited
      v) KMHP Ventures Limited
   B) Subsidiaries:
      i) Everyday Herbal Beauty Care Limited
      ii) Everyday Herbal Beauty and Wellness Care Private Limited
      iii) Globotask IT Consultancy Services Private Limited

7. In the Consolidated financial results, the Group has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 21872.57 lakhs and a corresponding Lease Liability of Rs. 23347.19 lakhs as at June 30, 2026. The impact of this on the consolidated profit for the quarter ended June 30, 2026 is Rs. 177.86 lakhs.

8. During the quarter, Company has made investments of:
   i) Rs. 2019.55 lakhs by subscribing 39,794 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, through right issue basis, at an issue price of Rs. 5,075/- (including the premium of Rs. 5,065/-) per equity.
   ii) Rs. 200.00 lakhs by subscribing 10,00,000 equity shares of M/s Curexis Ventures Private, Wholly Owned Subsidiary of the Company, Limited through right issue basis, at a price of Rs. 20/- (including premium of Rs. 10/-) per equity share.

Hmza

ZOTA HEALTHCARE LTD. *

Registered Office :
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :
Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

CIN : L24231GJ2000PLC038352

iii) Rs. 200.00 lakhs by subscribing 20,00,000 equity shares of M/s KMHP Ventures Limited, Wholly Owned Subsidiary of the Company, through right issue basis, at Rs. 10/- per equity share.

iv) Rs. 25.00 lakhs by acquiring 8,000 equity shares of M/s Globotask IT Consultancy Services Private Limited through right issue basis, at Rs. 312.50/- per equity share. Upon said acquisition, M/s Globotask IT Consultancy Services Private Limited became subsidiary of the Company.

9. Effective November 21, 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in the wages by Rs. 599.98 lakhs on the consolidated basis primarily arising due to change in the definition of "wages" for employees. Considering the materiality and non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Item" in the standalone and consolidated financial results for the quarter and year ended March 31, 2026.

10. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

ZOTA HEALTHCARE LTD.